Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta-analysis.
Lok AS, McMahon BJ, Brown RS Jr, Wong JB, Ahmed AT, Farah W, Almasri J, Alahdab F, Benkhadra K, Mouchli MA, Singh S, Mohamed EA, Abu Dabrh AM, Prokop LJ, Wang Z, Murad MH, Mohammed K.
Hepatology. 2016 Jan;63(1):284-306. doi: 10.1002/hep.28280. Epub 2015 Nov 13.
PMID:26566246
Non-linear association of baseline viral load with on-treatment hepatocellular carcinoma risk in chronic hepatitis B.
Choi WM, Kim GA, Choi J, Choi GH, Lee YB, Sinn DH, Lim YS.
Gut. 2024 Mar 7;73(4):649-658. doi: 10.1136/gutjnl-2023-330225.
PMID:37813567
Early antiviral treatment with tenofovir alafenamide to prevent serious clinical adverse events in adults with chronic hepatitis B and moderate or high viraemia (ATTENTION): interim results from a randomised controlled trial.
Lim YS, Yu ML, Choi J, Chen CY, Choi WM, Kang W, Kim GA, Kim HJ, Lee YB, Lee JH, Park NH, Kwon SY, Park SY, Kim JH, Choi GH, Jang ES, Chen CH, Hsu YC, Bair MJ, Cheng PN, Tung HD, Chang TS, Lo CC, Tseng KC, Yang SS, Peng CY, Han S.
Comparison of viral control between two tenofovir dose reduction regimens (300 mg every 48 hours versus 300 mg every 72 hours) in chronic hepatitis B patients with moderate renal impairment from tenofovir-induced renal dysfunction.
Chotiyaputta W, Poosanasuwansri K, Kiattisunthorn K, Chainuvati S, Tanwandee T.
2018 May 4. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–.
PMID:31643203
[Treatment of chronic viral hepatitis B in children with moderate doses of alpha interferon].